Business
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO annual meeting - Ended 1Q 2026 with $866.4 million in cash, sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetic
About this update from Cogent Biosciences, Inc.
[{"type":"image","alt":"Cogent Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cogent Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3g_c01A5xhx1astIu6oTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NQ--/https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141","width":300,"height":125}},"lazy":false},{"type":"text","content":"- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)","length":113,"tagName":"p"},{"type":"text","content":"- Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO annual meeting ","length":114,"tagName":"p"},{"type":"text","content":"- Ended 1Q 2026 with $866.4 million in cash, sufficient to fund operations into 2028","length":84,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass. and BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2026.","length":317,"tagName":"p"},{"type":"text","content":"“2026 is shaping up to be a pivotal year for Cogent,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “We have two NDAs for bezuclastinib under FDA review and expect to submit a third in the first half of this year. These milestones highlight the breadth of bezuclastinib’s potential across GIST and KIT-driven diseases. With a strong balance sheet, we are focused on completing our commercial build and preparing for multiple potential launches.”","length":468,"tagName":"p"},{"type":"text","content":"Recent Business Highlights","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced details for an oral presentation on May 30 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting featuring pivotal data from the Phase 3 PEAK trial in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib","length":279,"tagName":"p"}]},{"val":[{"type":"text","content":...